AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23645328 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective ECG-triggered sequential CCTA
Number of subjects: 100
Study 23645328 — intervention group
Group type: COMPARATOR
Intervention: Retrospective ECG-gated helical CT
Number of subjects: 100
Study 21299410 — intervention group
Group type: EXPERIMENTAL
Intervention: Forsus Fatigue Resistant Device (FRD)
Number of subjects: 32
Study 19723649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapuleucel-T (APC8024) administered via leukapheresis and infusions in weeks 0, 2, and 4.
Number of subjects: 18
Study 19723649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapuleucel-T (APC8024)
Number of subjects: 18
Study 17536083 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT acceptance group
Number of subjects: 455
Study 17536083 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT refusal group
Number of subjects: 455
Study 17536083 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 455
Study 15841810 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (n = 61)
Number of subjects: 173
Study 15841810 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine/xylitol/sorbitol chewing gum (n = 55)
Number of subjects: 173
Study 15841810 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride/xylitol/sorbitol chewing gum (n = 57)
Number of subjects: 173
Study 15841810 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no intervention, n = 232)
Number of subjects: 173
Study 11574740 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 110
Study 11574740 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 110
Study 11574740 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 110
Study 11574740 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide
Number of subjects: 110
Study 11574740 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory Blood Pressure (ABP) measurements
Number of subjects: 110
Study 11574740 — intervention group
Group type: COMPARATOR
Intervention: Clinic Blood Pressure (C) measurements
Number of subjects: 110
Study 10463739 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (nadroparin) - one daily subcutaneous injection, dosage adapted to body-weight
Number of subjects: 130
Study 10463739 — intervention group
Group type: COMPARATOR
Intervention: Mechanical prophylaxis (intermittent pneumatic compression)
Number of subjects: 130
Study 10463739 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (nadroparin)
Number of subjects: 130
Study 7640875 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (120 mg single dose or 90 mg daily for 23 days)
Number of subjects: 0
Study 7640875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2785260 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) applied to the contralateral leg
Number of subjects: 1
Study 2785260 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 1
Study 793500 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine hydrochloride
Number of subjects: 30
Study 793500 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine maleate
Number of subjects: 30
Study 793500 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 30
Study 30238238 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant Preservation (RP)
Number of subjects: 49
Study 30238238 — intervention group
Group type: COMPARATOR
Intervention: Remnant Debridement (RD)
Number of subjects: 49
Study 27194545 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling with care coordination (CCC)
Number of subjects: 606
Study 27194545 — intervention group
Group type: COMPARATOR
Intervention: Counseling alone (C)
Number of subjects: 606
Study 27194545 — intervention group
Group type: EXPERIMENTAL
Intervention: CCC
Number of subjects: 606
Study 27194545 — intervention group
Group type: COMPARATOR
Intervention: C
Number of subjects: 606
Study 25425451 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (metformin/pioglitazone/exenatide)
Number of subjects: 221
Study 25425451 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (metformin followed by sulfonylurea and glargine insulin)
Number of subjects: 221
Study 23171911 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of hydrocortisone orally
Number of subjects: 71
Study 23171911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 23171911 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of hydrocortisone orally in BPD patients with co-morbid PTSD
Number of subjects: 71
Study 23171911 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of hydrocortisone orally in BPD patients with co-morbid MDD
Number of subjects: 71
Study 21161466 — intervention group
Group type: EXPERIMENTAL
Intervention: People with melanoma
Number of subjects: 271
Study 21161466 — intervention group
Group type: COMPARATOR
Intervention: People never affected by melanoma
Number of subjects: 271
Study 19811337 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 19811337 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study 17105848 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with stenting
Number of subjects: 381
Study 17105848 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 381
Study 17105848 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 381
Study 17105848 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 381
Study 15589098 — intervention group
Group type: COMPARATOR
Intervention: Neuroasymptomatic (NAS)
Number of subjects: 100
Study 15589098 — intervention group
Group type: COMPARATOR
Intervention: AIDS dementia complex (ADC)
Number of subjects: 100
Study 11758322 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous bolus injection of 2% lidocaine 2 ml with infusion of propofol
Number of subjects: 80
Study 11758322 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of saline 2 ml, 10 s before propofol infusion
Number of subjects: 80
Study 11758322 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of lidocaine 2 ml, 10 s before propofol infusion
Number of subjects: 80
Study 11758322 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of saline 2 ml, 10 s before propofol infusion (control group)
Number of subjects: 80
Study 11758322 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous bolus injection of lidocaine with propofol
Number of subjects: 80
Study 9226526 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified formula B (enriched with sodium and potassium), n = 110
Number of subjects: 160
Study 9226526 — intervention group
Group type: COMPARATOR
Intervention: Standard formula A, n = 254
Number of subjects: 160
Study 9226526 — intervention group
Group type: COMPARATOR
Intervention: Mother's milk, n = 50
Number of subjects: 160
Study 9226526 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified formula B, n = 11
Number of subjects: 160
Study 9226526 — intervention group
Group type: COMPARATOR
Intervention: Standard formula A, n = 23
Number of subjects: 160
Study 7623170 — intervention group
Group type: COMPARATOR
Intervention: Hackethal nailing
Number of subjects: 40
Study 7623170 — intervention group
Group type: COMPARATOR
Intervention: Compression plating
Number of subjects: 40
Study 2928745 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida original mouthrinse (1508 ppm F)
Number of subjects: 12
Study 2928745 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 mouthrinse (241 ppm F)
Number of subjects: 12
Study 2928745 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida reduced mouthrinse (330 ppm F)
Number of subjects: 12
Study 2928745 — intervention group
Group type: EXPERIMENTAL
Intervention: ZH mouthrinse (287 ppm F)
Number of subjects: 12
Study 2928745 — intervention group
Group type: EXPERIMENTAL
Intervention: Act mouthrinse (308 ppm F)
Number of subjects: 12
Study 2928745 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida original and ZH mouthrinses
Number of subjects: 12
Study 2928745 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 and Act mouthrinses
Number of subjects: 12
Study 2928745 — intervention group
Group type: EXPERIMENTAL
Intervention: All mouthrinses
Number of subjects: 12
Study 2928745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinses after monofluorophosphate dentifrice
Number of subjects: 12
Study 2928745 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinsing with test agents after brushing with amine fluoride dentifrice (Elmex)
Number of subjects: 12
Study 2928745 — intervention group
Group type: EXPERIMENTAL
Intervention: In-between meals
Number of subjects: 12
Study 30756370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional nursing intervention based on glycemic load (GL)
Number of subjects: 134
Study 30756370 — intervention group
Group type: COMPARATOR
Intervention: Conventional nutritional nursing
Number of subjects: 134
Study 28525984 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus Fermentum CECT5716, daily for 8 weeks
Number of subjects: 600
Study 28525984 — intervention group
Group type: COMPARATOR
Intervention: Placebo, daily for 8 weeks
Number of subjects: 600
Study 26573042 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation programs
Number of subjects: 110
Study 26573042 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study 23149845 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B therapy (FAB/LMB 96 study)
Number of subjects: 42
Study 23149845 — intervention group
Group type: COMPARATOR
Intervention: non-MLBL DLBCL
Number of subjects: 42
Study 21685808 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Body Load (TBL) obtained from GPS devices
Number of subjects: 22
Study 21685808 — intervention group
Group type: EXPERIMENTAL
Intervention: Session Rating of Perceived Exertion (session-RPE)
Number of subjects: 22
Study 21685808 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided games training sessions
Number of subjects: 22
Study 18285717 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2b plus Ribavirin
Number of subjects: 87
Study 18285717 — intervention group
Group type: COMPARATOR
Intervention: Non-cirrhotic patients
Number of subjects: 87
Study 18285717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients not responding or relapsing after treatment
Number of subjects: 87
Study 18285717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with SVR
Number of subjects: 87
Study 16855066 — intervention group
Group type: EXPERIMENTAL
Intervention: Tennis specific fitness test (FT)
Number of subjects: 9
Study 16855066 — intervention group
Group type: COMPARATOR
Intervention: Treadmill test (TT)
Number of subjects: 9
Study 15256823 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal closure (group I)
Number of subjects: 54
Study 15256823 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal non-closure (group II)
Number of subjects: 54
Study 10637531 — intervention group
Group type: EXPERIMENTAL
Intervention: VOCs at 25 mg/m(3) for four hours
Number of subjects: 0
Study 10637531 — intervention group
Group type: EXPERIMENTAL
Intervention: VOCs at 50 mg/m(3) for four hours
Number of subjects: 0
Study 10637531 — intervention group
Group type: COMPARATOR
Intervention: Filtered air for four hours
Number of subjects: 0
Study 9310806 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration
Number of subjects: 28
Study 9310806 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hemofiltration)
Number of subjects: 28
Study 8317063 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intake of a polyethylene glycol solution (out-patient)
Number of subjects: 199
Study 8317063 — intervention group
Group type: COMPARATOR
Intervention: Oral intake of a polyethylene glycol solution (in-patient)
Number of subjects: 199
Study 2446061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg)
Number of subjects: 21
Study 2446061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg) plus Hydrochlorothiazide (25 mg)
Number of subjects: 21
Study 30325939 — intervention group
Group type: EXPERIMENTAL
Intervention: AL-335 800 mg QD in non-cirrhotic, GT1-4-infected subjects
Number of subjects: 112
Study 30325939 — intervention group
Group type: EXPERIMENTAL
Intervention: AL-335 800 mg QD in GT1-infected cirrhotic subjects
Number of subjects: 112
Study 30325939 — intervention group
Group type: COMPARATOR
Intervention: AL-335 (100-1,200 mg) in healthy volunteers
Number of subjects: 112
Study 30325939 — intervention group
Group type: COMPARATOR
Intervention: AL-335 (400, 800, 1,200 mg) in HCV-infected subjects
Number of subjects: 112
Study 30325939 — intervention group
Group type: COMPARATOR
Intervention: AL-335 (400 mg) in fed state
Number of subjects: 112
Study 30325939 — intervention group
Group type: COMPARATOR
Intervention: AL-335 (1,200 mg) in fasted state
Number of subjects: 112
Study 28391393 — intervention group
Group type: EXPERIMENTAL
Intervention: NZBC extract 600 mg day-1
Number of subjects: 15
Study 28391393 — intervention group
Group type: EXPERIMENTAL
Intervention: NZBC extract 900 mg day-1
Number of subjects: 15
Study 28391393 — intervention group
Group type: EXPERIMENTAL
Intervention: NZBC extract 300 mg day-1
Number of subjects: 15
Study 28391393 — intervention group
Group type: COMPARATOR
Intervention: No dose
Number of subjects: 15
Study 26052874 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician feedback intervention (CCFS) consisting of weekly performance feedback to clinicians and a clinical feedback report.
Number of subjects: 100
Study 26052874 — intervention group
Group type: COMPARATOR
Intervention: No feedback condition (control group).
Number of subjects: 100
Study 26052874 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician feedback intervention (CCFS)
Number of subjects: 100
Study 23411609 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg daily
Number of subjects: 969
Study 22332579 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucosamine hydrochloride (1.44 g daily) + intraarticular hyaluronate injection
Number of subjects: 28
Study 18643006 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced subordinate status
Number of subjects: 44
Study 18643006 — intervention group
Group type: COMPARATOR
Intervention: Induced dominant status
Number of subjects: 44
Study 16801645 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral STN stimulation
Number of subjects: 103
Study 14580925 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 19-8004 (5 mg once daily)
Number of subjects: 18
Study 14580925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10911768 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 159
Study 10911768 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 159
Study 10911768 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 159
Study 10911768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nutrition intervention and exercise
Number of subjects: 159
Study 8810971 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 242
Study 8810971 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 242
Study 8810971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 242
Study 1389989 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin
Number of subjects: 212
Study 1389989 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 212
Study 6380253 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 30
Study 30977496 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 59
Study 30977496 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FSO)
Number of subjects: 59
Study 30977496 — intervention group
Group type: COMPARATOR
Intervention: Control group (Corn oil, CO)
Number of subjects: 59
Study 30977496 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with metabolic risk factors
Number of subjects: 59
Study 29526243 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cancer treatment plus the ANITA program (integrative Tai Chi program including peer support, health education, and Tai Chi Ruler exercise)
Number of subjects: 24
Study 29526243 — intervention group
Group type: COMPARATOR
Intervention: Standard cancer treatment alone
Number of subjects: 24
Study 27154310 — intervention group
Group type: EXPERIMENTAL
Intervention: Merozoite antigens (specifically Rh5 codons 147 and 148)
Number of subjects: 0
Study 27154310 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic malaria infections
Number of subjects: 0
Study 27154310 — intervention group
Group type: COMPARATOR
Intervention: Complicated malaria infections
Number of subjects: 0
Study 27154310 — intervention group
Group type: EXPERIMENTAL
Intervention: All three malaria infection populations (uncomplicated, asymptomatic, complicated)
Number of subjects: 0
Study 25980150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal packing with pulmicort respules combined with nasopore after surgery
Number of subjects: 30
Study 25980150 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing with only nasopore after surgery
Number of subjects: 30
Study 22648913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg (test formulation)
Number of subjects: 24
Study 22648913 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline 400 mg (reference formulation)
Number of subjects: 24
Study 22648913 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 20478402 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐acetylcysteine pretreatment before a culture‐guided antibiotic regimen
Number of subjects: 40
Study 20478402 — intervention group
Group type: COMPARATOR
Intervention: No n‐acetylcysteine pretreatment (control group)
Number of subjects: 40
Study 17628824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of sodium bicarbonate (NaHCO3)
Number of subjects: 0
Study 17628824 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of calcium carbonate (CaCO3)
Number of subjects: 0
Study 16131376 — intervention group
Group type: EXPERIMENTAL
Intervention: Photochemically treated apheresis platelets (PCT)
Number of subjects: 43
Study 16131376 — intervention group
Group type: COMPARATOR
Intervention: Conventional apheresis platelets (reference)
Number of subjects: 43
Study 12027195 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium-free protocol (DFP) group with diazepam injection at 20:00 h and continuous infusion of flunitrazepam and pethidine for 8 hours for the first three nights postoperatively
Number of subjects: 42
Study 12027195 — intervention group
Group type: COMPARATOR
Intervention: Non-DFP group
Number of subjects: 42
Study 12027195 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium-free protocol (DFP) group
Number of subjects: 42
Study 10030314 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day screening mammography availability
Number of subjects: 920
Study 10030314 — intervention group
Group type: COMPARATOR
Intervention: Usual screening mammography scheduling
Number of subjects: 920
Study 7560363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugarless chewing gums (sweetened with sucrose, aspartame, saccharin, acesulfame-K, or xylitol)
Number of subjects: 8
Study 7560363 — intervention group
Group type: COMPARATOR
Intervention: No gum
Number of subjects: 8
Study 7560363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose gum
Number of subjects: 8
Study 2286596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg bd, intravenous for 3 days followed by oral for 7-10 days)
Number of subjects: 121
Study 2286596 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate (intravenous for 3 days followed by oral for 7-10 days)
Number of subjects: 121
Study 2286596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 121
Study 2286596 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate
Number of subjects: 121
Study 7109892 — intervention group
Group type: EXPERIMENTAL
Intervention: RUN‐CWT
Number of subjects: 77
Study 7109892 — intervention group
Group type: EXPERIMENTAL
Intervention: CWT
Number of subjects: 77
Study 7109892 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 77
Study 31836104 — intervention group
Group type: EXPERIMENTAL
Intervention: Win‐flash Perceptual Learning training
Number of subjects: 14
Study 31836104 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 14
Study 27881297 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and vitamin E co-supplementation
Number of subjects: 60
Study 27881297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26484516 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking group (NWg)
Number of subjects: 20
Study 26484516 — intervention group
Group type: COMPARATOR
Intervention: Control group (Cg)
Number of subjects: 20
Study 23868279 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint‐induced movement therapy
Number of subjects: 60
Study 23868279 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bilateral arm training with rhythmic auditory cueing
Number of subjects: 60
Study 23868279 — intervention group
Group type: COMPARATOR
Intervention: Dose‐matched conventional treatment
Number of subjects: 60
Study 21633398 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucaloric energy intake
Number of subjects: 42
Study 21633398 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% overfeeding
Number of subjects: 42
Study 19521296 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 260
Study 19521296 — intervention group
Group type: COMPARATOR
Intervention: Control (non-homozygous 4G/4G patients)
Number of subjects: 260
Study 17568029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 6 mg/kg
Number of subjects: 322
Study 17568029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 3 mg/kg
Number of subjects: 322